CNM-Au8, Clene Nanomedicine’s experimental oral therapy, safely and effectively improves vision and neurological function in adults with stable relapsing-remitting multiple sclerosis (RRMS) and disease-related visual impairment. Those are the findings of the VISIONARY-MS Phase 2 clinical trial (NCT03536559), a proof-of-concept study that investigated CNM-Au8 in people with multiple sclerosis (MS) who have vision problems.

U.S. government have declared a health emergency over the monkeypox outbreak. The U.S. Centers for Disease Control (CDC) has activated its Emergency Operations Center, and some observers fear containment may no longer be possible. People like me who study infectious diseases are asked every day: What should we be doing about it? To be clear, there […]

If a tree falls in a forest and nobody is around to hear it, does it make a sound? Similarly, if the U.S. Food and Drug Administration ultimately votes to approve Eli Lilly’s donanemab or Eisai’s lecanemab – both anti-amyloid beta (Aβ) antibodies – will it make an impact on Alzheimer’s disease (AD)? “The stupid […]